Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740825 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06740825 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 32 participants.
The verdict
NCT06740825, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects
Interventions
- DRUG Quizartinib
- DRUG Rufinamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2024-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06740825
The ClinicalTrials.gov registry entry for NCT06740825 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quizartinib is the first listed.
NCT06740825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06740825 about?
NCT06740825 is a clinical study titled "Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects". This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects
What is the current status of trial NCT06740825?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-10-29. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT06740825?
The interventions under investigation include: Quizartinib (DRUG), Rufinamide (DRUG).
Who is sponsoring clinical trial NCT06740825?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.